Boston Scientific (NYSE:BSX) Downgraded to Hold Rating by Wells Fargo & Company

Wells Fargo & Company downgraded shares of Boston Scientific (NYSE:BSX) from a strong-buy rating to a hold rating in a research note issued to investors on Thursday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. TD Cowen lowered their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Citigroup lowered their price target on Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a report on Thursday. Royal Bank Of Canada reissued an “outperform” rating on shares of Boston Scientific in a report on Thursday. Finally, UBS Group dropped their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $87.46.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $49.12 on Thursday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The company has a market cap of $73.01 billion, a PE ratio of 20.55, a P/E/G ratio of 0.93 and a beta of 0.62. The business has a 50-day simple moving average of $60.69 and a two-hundred day simple moving average of $78.84. Boston Scientific has a fifty-two week low of $48.41 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts expect that Boston Scientific will post 3.37 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig purchased 3,580 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. FWL Investment Management LLC acquired a new position in Boston Scientific in the second quarter valued at approximately $26,000. Murphy & Mullick Capital Management Corp lifted its holdings in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the period. Swiss RE Ltd. acquired a new position in Boston Scientific in the fourth quarter valued at approximately $26,000. United Community Bank lifted its holdings in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the period. Finally, Colonial Trust Co SC lifted its holdings in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.